D. Boral Capital Reaffirms “Buy” Rating for Plus Therapeutics (NASDAQ:PSTV)

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $3.00 price target on the stock.

Other equities analysts have also issued reports about the company. Ascendiant Capital Markets lowered their target price on Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $1.00 price target (down from $2.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. Finally, Lake Street Capital initiated coverage on shares of Plus Therapeutics in a report on Tuesday, February 3rd. They set a “buy” rating and a $2.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.60.

Plus Therapeutics Stock Up 2.1%

NASDAQ:PSTV traded up $0.01 on Thursday, hitting $0.24. The stock had a trading volume of 2,905,785 shares, compared to its average volume of 10,401,667. The business’s fifty day moving average is $0.29 and its 200 day moving average is $0.48. The company has a market cap of $41.34 million, a PE ratio of -0.19 and a beta of 0.79. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.08.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. L1 Global Manager Pty Ltd purchased a new stake in shares of Plus Therapeutics during the 4th quarter valued at $1,167,000. Jane Street Group LLC bought a new position in Plus Therapeutics during the fourth quarter valued at about $525,000. Altium Capital Management LLC bought a new position in Plus Therapeutics during the third quarter valued at about $628,000. Geode Capital Management LLC increased its holdings in Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after buying an additional 589,544 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Plus Therapeutics during the fourth quarter worth about $254,000. Hedge funds and other institutional investors own 3.28% of the company’s stock.

More Plus Therapeutics News

Here are the key news stories impacting Plus Therapeutics this week:

• Positive Sentiment: Company released a health‑economics analysis for its CNSide® diagnostic showing earlier detection of leptomeningeal metastases (LM) could cut LM healthcare costs by ~40% — a potentially important commercial and payer argument as CNSide moves into U.S. commercialization. Plus Therapeutics to Present New Analysis at ISPOR
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $1.00 target while raising several multi‑year forecasts (FY2026 improved from -$0.18 to -$0.15; FY2027 improved to -$0.10; FY2029 modeled as positive $0.12), signaling the broker expects recovery over the medium term. HC Wainwright analyst notes at MarketBeat
• Neutral Sentiment: The company is scheduled to report quarterly earnings this Thursday — an immediate catalyst that could swing the stock depending on revenue, commercialization updates for CNSide, or guidance. Plus Therapeutics (PSTV) to Release Quarterly Earnings
• Neutral Sentiment: Third‑party coverage: a brokers/analysts roundup published expectations and forecasts out to FY2030 — useful for longer‑term modeling but less likely to move price absent new data. Brokers Issue Forecasts for PSTV FY2030 Earnings
• Negative Sentiment: HC Wainwright cut near‑term quarterly EPS estimates (Q1–Q4 2026 and individual Q1/Q2/Q3 estimates moved from -$0.03 to -$0.04), reflecting weaker short‑term profitability assumptions — a downside pressure on the stock if investors focus on cash burn and near‑term losses. HC Wainwright lowers quarterly EPS estimates

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.